Infantile - Postoperative Residual Curarization - Study
Launched by UNIVERSITY OF REGENSBURG · Jan 13, 2019
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Residual neuromuscular block is known to be a significant but frequently overlooked complication after the use of neuromuscular blocking agents. Aim of this prospective, observational study is to detect the incidence and severity of residual paralysis at a tertiary academic german university medical center.
Methods:
All infantile patients recieving neuromuscular blocking agents are included over a 12 week observational period. At the end of the operation procedure, directly prior to tracheal extubation a train-of-four ratio was assessed quantitatively by an independet observer using the T...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • General aneasthesia with muscle relaxation
- • Children between 1 Month to 18 Years
- • Endotracheal Intubation due to surgical or diagnostical procedures
- Exclusion Criteria:
- • older than 18 years
- • local aneasthesia
- • regional aneasthesia
- • larynx mask
- • patient comes from ICU
- • children who are not planned to be extubated
About University Of Regensburg
The University of Regensburg is a prestigious academic institution located in Germany, renowned for its commitment to advancing medical research and education. With a strong emphasis on interdisciplinary collaboration, the university conducts innovative clinical trials aimed at improving patient outcomes and contributing to the global body of medical knowledge. The institution's research initiatives are supported by state-of-the-art facilities and a diverse team of experts across various fields, ensuring rigorous scientific methodologies and ethical standards. Through its clinical trial sponsorship, the University of Regensburg seeks to foster advancements in healthcare while promoting the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Regensburg, Bavaria, Germany
Patients applied
Trial Officials
Christoph Unterbuchner, MD
Principal Investigator
University medical center Regensburg, Department of anaesthesiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials